Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Rifabutin is marketed in Australia as Mycobutin.
Mycobacterium avium complex infection Clinical criteria: Patient must be human immunodeficiency virus (HIV) positive.
“Rifabutin has activity in vitro against laboratory strains and clinical isolates of M. tuberculosis.”
“The t 1/2 β of Mycobutin in humans is approximately 35-40 hours.”
“Therefore, as rifabutin has been shown to induce the enzymes of the cytochrome P450 3A subfamily, treatment may affect the pharmacokinetic behaviour of drugs metabolised by the enzymes belonging to that subfamily (as is seen with rifampicin).”
Rifabutin is marketed in Australia as Mycobutin.
1 brand name is recorded against this substance from the TGA eBS Product Information repository. The full list is in the Also known as card.
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.